Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain

Journal of Cerebral Blood Flow and Metabolism

Volumn 26, Issue 3, 2006, Pages 330-344

  Ginovart, Nathalie ^a,b   Meyer, Jeffrey H ^a,b   Boovariwala, Anahita ^a   Hussey, Doug ^a   Rabiner, Eugenii A ^c   Houle, Sylvain ^a,b   Wilson, Alan A ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

11C harmine; Human; Modeling; Monoamine oxidase; PET

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CARBON 11; HARMINE; MOCLOBEMIDE; RADIOLIGAND; TRACER;

ADULT; ARTICLE; BINDING SITE; BRAIN; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTRIBUTION VOLUME; FRONTAL CORTEX; HUMAN; KINETICS; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RELIABILITY; TEMPORAL CORTEX; THALAMUS;

ADULT; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; HARMINE; HUMANS; KINETICS; MALE; MIDDLE AGED; MOCLOBEMIDE; MODELS, BIOLOGICAL; MONOAMINE OXIDASE; PLACEBOS; POSITRON-EMISSION TOMOGRAPHY; REFERENCE VALUES; TIME FACTORS;

EID: 33644499859     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600197     Document Type: Article

References (60)

1. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Bremner JD, Hyde TM, Charney DS et al (1994) SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med 35:228-38
2. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr 19:716-23
3. 11C]brofaromine, a potential tracer for imaging monoamine oxidase A. Nucl Med Biol 23:229-34
4. Angst J, Stabl M (1992) Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology (Berlin) 106(Suppl):S109-13
5. 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. Nucl Med Biol 24:381-8
6. Bergstrom M, Westerberg G, Langstrom B (1997b) 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol 24:287-93
7. Bergstrom M, Westerberg G, Nemeth G, Traut M, Gross G, Greger G, Muller-Peltzer H, Safer A, Eckernas SA, Grahner A, Langstrom B (1997c) MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur J Clin Pharmacol 52:121-8
8. Bonnet U (2003) Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 9:97-140
9. Bonvento G, Lacombe P, Seylaz J (1989) Effects of electrical stimulation of the dorsal raphe nucleus on local cerebral blood flow in the rat. J Cereb Blood Flow Metab 9:251-5
10. 11C]befloxatone. J Pharmacol Exp Ther 305:467-73
11. Buck A, Westera G, vonSchulthess GK, Burger C (1996) Modeling alternatives for cerebral carbon-11-iomazenil kinetics. J Nucl Med 37:699-705
12. Carson RE (1986) Parameters estimation in positron emission tomography. In: Positron emission tomography. Principles applications for the brain and the heart (Phelps ME, Mazziota JC, Schelbert HR, eds), New York: Raven Press, 347-90
13. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24-42
14. Cohen G (1990) Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm Suppl 32:229-38
15. Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE (1989) Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl 28:5-20
16. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708
17. Fowler JS, Logan J, Wang GJ, Franceschi D, Volkow ND, Telang F, Pappas N, Ferrieri R, Shea C, Garza V, Xu Y, King P, Schlyer D, Gatley SJ, Ding YS, Warner D, Netusil N, Carter P, Jayne M, Alexoff D, Zhu W, Vaska P (2003) Monoamine oxidase A imaging in peripheral organs in healthy human subjects. Synapse 49:178-87
18. 11C-labeled suicide inactivators and PET. Science 235:481-5
19. Fowler CJ, Wiberg A, Oreland L, Danielsson A, Palm U, Winblad B (1981) Monoamine oxidase activity and kinetic properties in platelet-rich plasma from controls, chronic alcoholics, and patients with nonalcoholic liver disease. Biochem Med 25:356-65
20. 11C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 21:1342-53
21. Grome JJ, Harper AM (1983) The effects of serotonin on local cerebral blood flow. J Cereb Blood Flow Metab 3:71-7
22. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF (2000) Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 27:627-30
23. Holschneider DP, Scremin OU, Huynh L, Chen K, Seif I, Shih JC (2000) Regional cerebral cortical activation in monoamine oxidase A-deficient mice: differential effects of chronic versus acute elevations in serotonin and norepinephrine. Neuroscience 101:869-77
24. Holzgrabe U, Mohr K (1998) Allosteric modulators of ligand binding to muscarinic acetylcholine receptors. Drug Discovery Today 3:214-22
25. Jarman J, Glover V, Sandler M, Turjanski N, Stern G (1993) Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation. J Neural Transm Park Dis Dement Sect 5:1-4
26. Kim H, Sablin SO, Ramsay RR (1997) Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 337:137-42
27. 11C] dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab 16:1288-1299
28. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735-44
29. Landaw EM, DiStefano JJ, III (1984) Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol 246:R665-677
30. Lewine RJ, Meltzer HY (1984) Negative symptoms and platelet monoamine oxidase activity in male schizophrenic patients. Psychiatry Res 12:99-109
31. Lipper S, Murphy DL, Slater S, Buchsbaum MS (1979) Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berlin) 62:123-8
32. Litton J, Holte S, Eriksson L (1990) Evaluation of the Karolinska new positron camera: the Scanditronix PC2048-15B. IEEE Trans Nucl Sci NS 37:743-8
33. Livingston MG, Livingston HM (1996) Monoamine oxidase inhibitors. An update on drug interactions. Drug Saf 14:219-27
34. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-7
35. 11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 14:995-1010
36. Logan J, Wolf AP, Shiue CY, Fowler JS (1987) Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers. J Neurochem 48:73-83
37. 11C]Scherring 23390. IXth International Symposium on Radiopharmaceutical Chemistry, Paris, K15
38. Mann J, Chiu E (1978) Platelet monoamine oxidase activity in Huntington's chorea. J Neurol Neurosurg Psychiatry 41:809-12
39. Mann JJ, Stanley M (1984) Postmortem monoamine oxidase enzyme kinetics in the frontal cortex of suicide victims and controls. Acta Psychiatr Scand 69:135-9
40. Marquardt DW (1963) An algorithm for least-squares estimation on non-linear parameters. J Soc Ind Appl Math 11:431-41
41. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-27
42. Murphy DL, Weiss R (1972) Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. Am J Psychiatry 128:1351-7
43. Nair NP, Ahmed SK, Kin NM (1993) Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J Psychiatry Neurosci 18:214-25
44. Ohmomo Y, Hirata M, Murakami K, Magata Y, Tanaka C, Yokoyama A (1991) Synthesis of fluorine and iodine analogues of clorgyline and selective inhibition of monoamine oxidase A. Chem Pharm Bull (Tokyo) 39:1038-40
45. 11C-labeled fluoroclorgyline: a monoamine oxidase A specific inhibitor for positron emission tomography. Chem Pharm Bull (Tokyo) 41:1994-7
46. Ordway GA, Farley JT, Dilley GE, Overholser JC, Meltzer HY, Balraj EK, Stockmeier CA, Klimek V (1999) Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res 847:71-9
47. Oreland L, Fowler CJ, Schalling D (1981) Low platelet monoamine oxidase activity in cigarette smokers. Life Sci 29:2511-8
48. Phelps ME, Huang SC, Hoffman EJ, Kuhl DE (1979) Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin. J Nucl Med 20:328-34
49. 11C]flumazenil. J Cereb Blood Flow Metab 13:656-67
50. Saura J, Bleuel Z, Ulrich J, Mendelowitsch A, Chen K, Shih JC, Malherbe P, Da Prada M, Richards JG (1996a) Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 70:755-74
51. 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12:1977-99
52. Saura J, Nadal E, van den Berg B, Vila M, Bombi JA, Mahy N (1996b) Localization of monoamine oxidases in human peripheral tissues. Life Sci 59:1341-9
53. Sherif F, Marcusson J, Oreland L (1991) Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims. Eur Arch Psychiatry Clin Neurosci 241:139-44
54. Shih JC, Chen K, Ridd MJ (1999) Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22:197-217
55. Studholme C, Hill DLG, Hawkes DJ (1997) Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimisation of voxel similarity measures. Med Phys 24:25-35
56. Szabo L, Kovach AG, Babosa M, Greenberg JH, Revich M (1983) Effect of sustained norepinephrine infusion on local cerebral blood flow in the rat. Circ Shock 10:101-117
57. Waldmeier PC (1985) On the reversibility of reversible MAO inhibitors. Naunyn Schmiedebergs Arch Pharmacol 329:305-10
58. 3]-carbomethoxy-3β- aryltropanes: radiotracers for the dopamine transporter. J Labelled Compd Radiopharm 34:759-65
59. 11C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 27:529-32
60. Youdim MB (1988) Platelet monoamine oxidase B: use and misuse. Experientia 44:137-41